LOXL3 and liver cancer: In summary, we applied Leflunomide, a DHODH inhibitor, to block AK2–LOXL3–DHODH axis transduction, and to enhance the sensitivity of liver cancer cells to Oxaliplatin treatment by increasing ferroptosis (Fig. 7f).